| Antiniece Nicole Mcphearson, | |
|
505 E Kalamazoo Ave Ste A, Kalamazoo, MI 49007-3873 | |
| (314) 728-0474 | |
| Not Available |
| Full Name | Antiniece Nicole Mcphearson |
|---|---|
| Gender | Female |
| Speciality | Nurse's Aide |
| Location | 505 E Kalamazoo Ave Ste A, Kalamazoo, Michigan |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184339533 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164W00000X | Licensed Practical Nurse | 2021036978 (Missouri) | Secondary |
| 376K00000X | Nurse's Aide | (* (Not Available)) | Primary |
| 376K00000X | Nurse's Aide | 141824 (Missouri) | Secondary |
| Mailing Address | Practice Location Address |
|---|---|
| Antiniece Nicole Mcphearson, 4056 Finney Ave, Saint Louis, MO 63113-3426 Ph: (314) 728-0474 | Antiniece Nicole Mcphearson, 505 E Kalamazoo Ave Ste A, Kalamazoo, MI 49007-3873 Ph: (314) 728-0474 |
News Archive
Scientists at the University of California at Berkeley have devised a method by which they can hear thoughts. They conducted a small study in which they could predict what people were thinking based on their brain activity.
Researchers at VIB, KU Leuven, and UZ Leuven, in collaboration with researchers at the University of Jena, have demonstrated that measuring neurofilaments provides reliable confirmation of an ALS diagnosis.
How do we know where we are at any given moment? How do we remember routes that we've walked? Spatial navigation has long been a subject of psychological and brain research. "It is likely that there is more than one spatial navigation mechanism; rather, the brain uses different 'codes' to memorise locations," says Nikolai Axmacher.
Edge Therapeutics, a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies for acute, life-threatening neurological conditions, today announced that it has initiated patient enrollment in the second cohort of the NEWTON study, a multicenter, randomized, controlled, open-label, Phase 1/2 clinical trial of the company's lead product candidate, EG-1962.
› Verified 8 days ago